Wnt signaling has been intensively studied by bone biologists since the discovery that loss-of-function mutations in low-density lipoprotein receptor-related protein 5 (LRP5), a coreceptor for Wnt ligands, underlie the hereditary disease osteoporosis pseudoglioma (OPPG) (Gong et al., 2001) . Conversely, gainof-function mutations in LRP5 cause high bone mass syndromes in humans (Boyden et al., 2002; Little et al., 2002) . Additional studies have implicated Wnt signaling in the production and function of osteoblasts (bone-forming cells) including genetic deletion of β-catenin, a central component of the canonical Wnt pathway, which results in a complete lack of mature osteoblasts in the mouse (Day et al., 2005; Hill et al., 2005; Hu et al., 2005; Rodda and McMahon, 2006) . Therefore, a current prevailing model posits that canonical Wnt signaling via the cell-surface molecule LRP5, or the related protein LRP6, directly controls osteoblast formation or function. However, direct genetic evidence linking the role of LRP5 in bone formation with canonical Wnt signaling in osteoblasts has been lacking. In this issue of Cell, Yadav et al. (2008) provide compelling evidence that Lrp5 indirectly enhances bone formation through inhibition of serotonin production in the mouse duodenum, thereby revealing the existence of a gut-to-bone endocrine axis.
Prior work provided hints that canonical Wnt signaling in bone might not be sufficient by itself to explain the effects of LRP5 mutations on bone mass. Mice lacking Lrp5 in all cells, similar to patients with OPPG, exhibit low bone mass during early postnatal life, owing to decreased osteoblast proliferation and function (Kato et al., 2002 ). Yet, mice lacking β-catenin specifically in more mature osteoblasts due to expression of Cre-recombinase under the control of the collagen I promoter (ColI-Cre) do not display a clear osteoblast phenotype. These mice do show increased formation of osteoclasts (bone-degrading cells) secondary to a decrease in the osteoblast-derived anti-osteoclastogenic factor osteoprotegerin (OPG) (Glass et al., 2005) . This discrepancy suggested that the osteoblast defect caused by Lrp5 deficiency may occur at an earlier stage of osteoblast development than is targeted by the ColI-Cre transgene. Alternatively, Lrp5 may control bone formation either independently of β-catenin or not through direct effects on osteoblasts, or both.
To shed light on the molecular mechanism through which LRP5 controls bone formation, Yadav et al. (2008) performed microarray experiments with RNA extracted from wild-type and Lrp5-deficient mouse bones. They discovered that the most highly expressed gene in mutant bone tissue compared with wildtype was Tph1, which encodes trypto-phan hydroxylase, a rate-limiting enzyme for serotonin synthesis in the enterochromaffin cells of the duodenum. Indeed, Tph1 mRNA was also greatly upregulated in the duodenum, and serum serotonin levels were markedly increased in Lrp5-deficient mice. Because serotonin has been implicated in regulating the accrual of bone mass (Warden et al., 2005) , this finding raised the possibility that Lrp5 may exert its function on bone through gut-derived serotonin. The authors vigorously tested this hypothesis.
The authors first show that Lrp5 functions through the gut, instead of bone, to promote bone mass accrual. Gut-specific deletion of Lrp5 (using a Villin-Cre transgene) recapitulates the same low bone mass phenotype as the Lrp5 null mice, which is characterized by reduced mineral apposition rate and decreased osteoblast proliferation concurrent with reduction of the cyclins D1, D2, and E1. In contrast, osteoblast-specific deletion of Lrp5 does not cause a similar osteoblast defect. In converse experiments, gutspecific expression of an Lrp5 allele harboring a mutation that leads to high bone mass causes a high bone mass phenotype, whereas expression of the same allele in osteoblasts fails to do so. Importantly, mice with gut-specific deletion of Lrp5 exhibit an increased level of serum serotonin, whereas the gut-specific expression of a high bone mass Lrp5 allele causes a decrease in serum serotonin levels. Similar genetic manipulations in osteoblasts, however, do not alter the serum serotonin levels. Remarkably, the low bone mass phenotype in Lrp5-deficient mice is reversed upon lowering of serotonin levels by either a diet low in tryptophan or an inhibitor of serotonin synthesis. These results therefore demonstrate that Lrp5 functions predominantly in the gut, but not in osteoblasts, to stimulate osteoblast proliferation. Furthermore, gutderived serotonin may be a key mediator of Lrp5 function.
Indeed, gut-derived serotonin negatively controls bone mass. Gut-specific deletion of Tph1 drastically reduces serum serotonin levels and also increases bone mass. Conversely, osteoblast-specific deletion of Tph1 has no effect on bone mass, indicating that Tph1, although reduced in the bones of Lrp5-deficient mice, does not appear to play a direct role in bone formation. Furthermore, circulating serotonin appears to inhibit bone formation by signaling specifically through the serotonin receptor HTR1B in osteoblasts; HTR1B signaling in turn inhibits both expression and phosphorylationdependent activation of the transcription factor CREB, which itself is necessary for optimal expression of cyclin D1 and presumably for normal osteoblast proliferation. Interestingly, the mice that lack expression of Tph1 in the gut appear to be resistant to bone loss due to ovariectomy, even though bone resorption is induced in these mice.
The authors also provide evidence that Lrp5 and serotonin function genetically in the same pathway. In particular, removal of either one Tph1 allele from the gut or one Htr1b allele globally normalizes bone mass in the Lrp5-deficient mice.
The study does not rule out the possibility that Lrp5 may directly regulate osteoblast differentiation in bone postnatally. However, the study does restrict any such potential regulation to a developmental stage prior to that targeted by the ColI-Cre transgene. Moreover, such a potential role does not appear to contribute significantly to the bone parameters assayed in this study and therefore, by inference, may not be the main cause of the bone defect in OPPG patients. A model in which serotonin has a primary role is also consistent with the observation that circulating serotonin was significantly elevated in several OPPG patients.
The molecular mechanism through which Lrp5 inhibits Tph1, and consequently decreases serotonin expression in the enterochromaffin cells, is not understood. Although Wnt signaling is known to regulate cell fates in the intestine, Lrp5 does not appear to alter the identity and organization of cell types in the duodenum. Lrp5 could function through Wnt signaling to regulate Tph1 expression, although the authors do not observe a genetic interaction between Lrp5 and β-catenin in bone mass regulation. Alternatively, Lrp5 may function in a yet unknown context to inhibit Tph1 expression. Finally, Lrp5 may have other mediators in the intestine besides Tph1 and serotonin. This possibility is consistent with the observation that the effect of gut-specific deletion of Tph1 on bone is less severe than the phenotype resulting from the gut-specific expression of the high bone mass allele of Lrp5, even though the level of serum serotonin in the Tph1-deficient mice is markedly lower than that found in the Lrp5 mouse model.
The discovery of LRP5 as the disease gene in OPPG patients ushered in a new era of studying Wnt signaling in bone, which in turn has led to substantial evidence that this pathway exerts direct regulation on the osteoblast lineage. The new study by Yadav et al. now calls into question the physiological relevance of direct bone Wnt-Lrp5 signaling in the pathogenesis of OPPG. One cannot help asking, have we once again been studying the right molecule for the wrong reason?
